1. Home
  2. ACRS vs PSNYW Comparison

ACRS vs PSNYW Comparison

Compare ACRS & PSNYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$4.54

Market Cap

311.0M

Sector

Health Care

ML Signal

HOLD

Logo Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

PSNYW

Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

N/A

Current Price

$3.03

Market Cap

290.9M

ML Signal

N/A

Company Overview

Basic Information
Metric
ACRS
PSNYW
Founded
2012
2017
Country
United States
Sweden
Employees
N/A
1686
Industry
Biotechnology: Pharmaceutical Preparations
Auto Manufacturing
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
311.0M
290.9M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
ACRS
PSNYW
Price
$4.54
$3.03
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$10.20
N/A
AVG Volume (30 Days)
1.4M
5.1K
Earning Date
05-07-2026
03-06-2025
Dividend Yield
N/A
N/A
EPS Growth
69.01
N/A
EPS
N/A
N/A
Revenue
$1,683,000.00
$2,034,261,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.24
$79.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.22
$0.14
52 Week High
$5.15
$7.50

Technical Indicators

Market Signals
Indicator
ACRS
PSNYW
Relative Strength Index (RSI) 53.18 47.87
Support Level $4.08 $2.88
Resistance Level $5.02 $3.51
Average True Range (ATR) 0.26 0.23
MACD -0.06 0.04
Stochastic Oscillator 38.04 48.28

Price Performance

Historical Comparison
ACRS
PSNYW

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

Polestar Automotive Holding UK PLC is a pure play, premium electric car brand, designing performance cars engineered to excite consumers and drive change. It believes that it defines market standards in design, innovation and sustainability. It is determined to improve society by accelerating the shift to sustainable mobility. The company conducts its business as one operating segment with primary commercial operations in Europe, North America, Asia Pacific and various importer markets. The company generates majority of revenue from United Kingdom.

Share on Social Networks: